NCT00059995View on ClinicalTrials.gov

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2003

Primary Completion Date

October 31, 2007

Study Completion Date

November 30, 2009

Conditions
Lymphoma
Interventions
BIOLOGICAL

iratumumab

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

55905

Mayo Clinic Cancer Center, Rochester

43210-1240

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00059995 - MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma | Biotech Hunter | Biotech Hunter